ATS 2024 Final Program

Click on the session title to view the speakers

279

TUESDAY • MAY 21

P121 Reduced Natural Killer Cell Activity in Individuals With Cystic Fibrosis Is Mediated by Decreased NKp30 Expression P122 Evaluation of KB407, An HSV-1-Based Gene Therapy Vector for the Treatment of Cystic Fibrosis, in Healthy and Patient-Derived Airway Cells Including an Apical-out Diseased Airway Organoid Model P123 The Orai1 Antagonist ELD607 Safely Reduces Lung Inflammation in G551D Cystic Fibrosis Ferrets P124 Dysbiosis of the Oral Microbiome Is Associated With Pulmonary Function, Chronic Antibiotic Use and Inhaled DNase Therapy in People With CF Receiving HEMT P125 Rapid Reversal of Mucociliary Transport Defects in G551D Neonatal Pigs P126 Role of DNAJB11 in CFTR Expression and Degradation P127 Comparison of the Effectiveness of Angiotensin Receptor Blockers in Reversing TGF-ß1-Induced CFTR and Mucociliary Dysfunction in Cystic Fibrosis Airway Epithelial Cells P128 Understanding Impact of CFTR Dysfunction on Airway Immune Cell Composition in Early Lung Disease Pathogenesis P129 Regional Susceptibility to Hypoxia-induced Changes in Airway Lipid Composition and Implications in Muco-obstructive Lung Diseases P130 Development of a CF Monocyte Model for Investigating the Role of Immune Dysfunction in CF Disease Onset and Progression P131 Targeting IL-6 and Endothelin Axis Enables Alveolar Growth in Mechanically Ventilated Newborn Mice P132 Caffeine Promotes Epithelial Wound Healing Through a TGFß-dependent Pathway

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

C71 ASTHMA CLINICAL PHENOTYPES AND THERAPIES 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area F (Hall A-B2, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P690 Rapid and Persistent 6-week Response to ICS/LABA/LAMA in Mild-moderate Asthma P691 Small Airway Asthma Phenotype Has Higher Type 2 Biomarker Levels Than Patients With Normal Lung Function P692 An Analysis of the Accuracy of Digital Home Peak Flow Monitoring, Relative to Supervised Measurements, in Uncontrolled Asthma P693 Prevalence of Small Airways Dysfunction as Defined by R5-R20 on Oscillometry in the Asthmatic Population and Its Co-relation With Spirometry: Findings From the Arise Network P694 Airway pH Is Low in Asthma: Assessment Using Buffer Inhalation P695 Effects of Benralizumab on Mucus Plugs in Eosinophilic Severe Asthma P696 Diagnostic Accuracy of Impulse Oscillometry for the Diagnosis of Asthma in Preschool Children, in a High Altitude Reference Institution P697 At-home Handheld Spirometry Quality in Patients With Moderate Asthma P698 Increased Abdominal Visceral Fat Relative to Erector Spinae Muscle on Computed Tomography and Impaired Asthma Related Quality of Life P699 Mucus Plugs Associated With Dupilumab Induction in Severe Asthma P700 Prenatal Omega-3 Fatty Acid Status in High-risk Pregnant Women With Asthma

ATS 2024 Conference Program • San Diego, CA